Egetis Therapeutics AB (publ)

OM:EGTX Rapport sur les actions

Capitalisation boursière : SEK 1.5b

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Egetis Therapeutics Croissance future

Future contrôle des critères 5/6

Egetis Therapeutics is forecast to grow earnings and revenue by 98.6% and 70.2% per annum respectively while EPS is expected to grow by 92.7% per annum.

Informations clés

98.6%

Taux de croissance des bénéfices

92.7%

Taux de croissance du BPA

Biotechs croissance des bénéfices44.8%
Taux de croissance des recettes70.2%
Rendement futur des capitaux propresn/a
Couverture par les analystes

Low

Dernière mise à jour12 Aug 2024

Mises à jour récentes de la croissance future

Recent updates

Is Egetis Therapeutics (STO:EGTX) Using Debt Sensibly?

Aug 20
Is Egetis Therapeutics (STO:EGTX) Using Debt Sensibly?

Here's Why We're Not Too Worried About Egetis Therapeutics' (STO:EGTX) Cash Burn Situation

May 26
Here's Why We're Not Too Worried About Egetis Therapeutics' (STO:EGTX) Cash Burn Situation

We're Keeping An Eye On Egetis Therapeutics' (STO:EGTX) Cash Burn Rate

Dec 21
We're Keeping An Eye On Egetis Therapeutics' (STO:EGTX) Cash Burn Rate

Will Egetis Therapeutics (STO:EGTX) Spend Its Cash Wisely?

Jun 07
Will Egetis Therapeutics (STO:EGTX) Spend Its Cash Wisely?

Is Egetis Therapeutics AB (publ) (STO:EGTX) Trading At A 30% Discount?

Jan 19
Is Egetis Therapeutics AB (publ) (STO:EGTX) Trading At A 30% Discount?

Egetis Therapeutics AB (publ) (STO:EGTX) Is Expected To Breakeven In The Near Future

Mar 22
Egetis Therapeutics AB (publ) (STO:EGTX) Is Expected To Breakeven In The Near Future

What Type Of Returns Would Egetis Therapeutics'(STO:EGTX) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Feb 15
What Type Of Returns Would Egetis Therapeutics'(STO:EGTX) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

What You Need To Know About Egetis Therapeutics AB (publ)'s (STO:EGTX) Investor Composition

Jan 20
What You Need To Know About Egetis Therapeutics AB (publ)'s (STO:EGTX) Investor Composition

Egetis Therapeutics AB (publ) (STO:EGTX) Insiders Increased Their Holdings

Dec 24
Egetis Therapeutics AB (publ) (STO:EGTX) Insiders Increased Their Holdings

Prévisions de croissance des bénéfices et des revenus

OM:EGTX - Estimations futures des analystes et données financières antérieures (SEK Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/202644879284953
12/31/202549110760885
12/31/202456-293-257-2875
3/31/202463-327-254-254N/A
12/31/202358-327-278-278N/A
9/30/202331-318-299-299N/A
6/30/202324-286-249-249N/A
3/31/202322-240-220-220N/A
12/31/202223-194-173-173N/A
9/30/202220-148-137-137N/A
6/30/202221-113-125-125N/A
3/31/202242-114-128-128N/A
12/31/202138-104-130-130N/A
9/30/202140-147-143-143N/A
6/30/202136-153-137-137N/A
3/31/202133-155-133-133N/A
12/31/202041-178-135-135N/A
9/30/202053-127-124-124N/A
6/30/202056-134-134-134N/A
3/31/202039-127-127-127N/A
12/31/201983-61-63-63N/A
9/30/201977-61-54-54N/A
6/30/201977-48-38-38N/A
3/31/201982-46-39-39N/A
12/31/201828-85-81-81N/A
9/30/201831-95-106-106N/A
6/30/201824-103-97-97N/A
3/31/201814-91-90-90N/A
12/31/201714-88N/A-87N/A
9/30/2017N/A-67N/A-51N/A
6/30/20170-48N/A-49N/A
3/31/2017N/A-44N/A-41N/A
12/31/2016N/A-38N/A-36N/A
9/30/2016N/A-36N/A-36N/A
6/30/2016N/A-39N/A-38N/A
3/31/2016N/A-39N/A-44N/A
12/31/2015N/A-44N/A-51N/A
9/30/2015N/A-53N/A-55N/A
6/30/2015N/A-53N/A-52N/A
3/31/2015N/A-54N/A-47N/A
12/31/2014N/A-48N/A-41N/A
9/30/2014N/A-38N/A-34N/A
6/30/2014N/A-31N/A-31N/A
3/31/2014N/A-24N/A-25N/A
12/31/2013N/A-26N/A-28N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: EGTX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.1%).

Bénéfices vs marché: EGTX is forecast to become profitable over the next 3 years, which is considered above average market growth.

Croissance élevée des bénéfices: EGTX is expected to become profitable in the next 3 years.

Chiffre d'affaires vs marché: EGTX's revenue (70.2% per year) is forecast to grow faster than the Swedish market (1% per year).

Croissance élevée des revenus: EGTX's revenue (70.2% per year) is forecast to grow faster than 20% per year.


Prévisions de croissance du bénéfice par action


Rendement futur des capitaux propres

ROE futur: Insufficient data to determine if EGTX's Return on Equity is forecast to be high in 3 years time


Découvrir les entreprises en croissance